论文部分内容阅读
双喃氟啶(FD-1)是一个新的抗代谢类抗肿瘤药物,它与抗癌药喃氟啶(FT-207)同属于5-氟尿嘧啶(5-Fu)的衍生物。化学名:1,3-双(四氢呋喃基)-5-氟尿嘧啶。经动物实验结果表明:口服双喃氟啶后在血和组织中的5-Fu浓度比口服喃氟啶后的5-Fu浓度高5～7倍;尤其在肿瘤组织中的5-Fu浓度前者比后者要高8～12倍。双喃氟啶的毒性仅为喃氟啶的1/3左右。又经生化研究阐明,双喃氟啶系通过二条途径代谢为5-Fu,一条途径先代谢为喃氟啶;另一条途径先代谢为3-FT,它的抑瘤率较FT-207和FD-1都高,因而双喃氟啶对胃
Di-fluoropyridine (FD-1) is a new antimetabolite antitumor agent, which belongs to the 5-fluorouracil (5-Fu) derivative together with the anticancer drug, fluoropyridine (FT-207) Chemical name: 1,3-bis (tetrahydrofuryl) -5-fluorouracil. The results of animal experiments show that the 5-Fu concentration in blood and tissues after oral administration of diazafluoride is 5 to 7 times higher than that of oral exposure to famofluidine, especially in the tumor tissues 8 to 12 times higher than the latter. The toxicity of bisfluoropyridine is only about 1/3 of the flukeridine. Biochemical studies have shown that the biofuluidine is metabolized to 5-Fu through two channels, one of which is first metabolized to flunaridipine. The other pathway is metabolized to 3-FT, which is more effective than FT-207 and FD -1 are high, so double fluoride fluorine on the stomach